Quantcast

Global Type 1 Diabetes Drugs Market 2019-2023 | Evolving Opportunities with Eli Lilly and Merck | Technavio

LONDON–(BUSINESS WIRE)–#Biotechnology–Technavio has been monitoring the global type 1 diabetes drugs market since 2016 and the market is poised to grow by USD 12 billion during 2019-2023, progressing at a CAGR of over 7% during the forecast period. Request Free Sample Pages


Read the 127-page research report with TOC on “Type 1 Diabetes Drugs Market Analysis Report by Product (Long-acting insulins, Rapid-acting insulins, Pre-mixed insulins, and Non-insulin drugs), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 – 2023.”

https://www.technavio.com/report/global-type-1-diabetes-drugs-market-industry-analysis

The growing prevalence of type 1 diabetes and advances in insulin delivery devices are factors anticipated to boost the growth of the market.

The incidence of type 1 diabetes is rising due to various factors such as genetic mutations, growing population, and environmental factors. Patients with Type 1 diabetes experience destruction of the beta-cells of the islets of Langerhans in the pancreas, which produces insulin. Certain viruses can trigger an auto-immune response, ultimately leading to type 1 diabetes. People who experience mutations in the genes encoding the human leukocyte antigen (HLA) such as the HLA-DQA1, HLA-DQB1, and HLA-DRB1 genes are also susceptible to type 1 diabetes. Thus, the growing prevalence of type 1 diabetes is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Type 1 Diabetes Drugs Market Companies:

Astellas Pharma

Astellas Pharma is headquartered in Japan and operates the business under the Pharmaceuticals segment. The company offers SYMLIN, which is an amylin analog indicated in patients with type 1 or type 2 diabetes.

Eli Lilly

Eli Lilly is headquartered in the US and offers products through the following business units: Human pharmaceutical products and Animal health products. The company offers Humalog, which is a rapid-acting insulin analog indicated to improve glycemic control.

Merck

Merck is headquartered in the US and operates under various business segments, namely Pharmaceutical and Other segments. The company offers LUSDUNA, which is an insulin glargine biosimilar and is under the pre-registration phase.

Novo Nordisk

Novo Nordisk is headquartered in Denmark and offers products through the following business segments: Diabetes care and obesity and Biopharmaceuticals. The company offers Levemir, NovoLog/NovoRapid, NovoLog Mix 70/30, and Tresiba.

Sanofi

Sanofi is headquartered in France and offers products through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The company offers LANTUS, Toujeo, APIDRA, Admelog, and Ryzodeg 70/30.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Type 1 Diabetes Drugs Product Outlook (Revenue, USD Million, 2019 – 2023)

  • Long-acting insulins
  • Rapid-acting insulins
  • Pre-mixed insulins
  • Non-insulin drugs

Type 1 Diabetes Drugs Regional Outlook (Revenue, USD Million, 2019 – 2023)

  • Asia
  • Europe
  • North America
  • ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]
Website: https://www.technavio.com

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.